Nervous Disorder TRIZ Cases

A once-per-cycle 0.06 mg/kg thrombomodulin infusion helps prevent and mitigate oxaliplatin-induced peripheral neuropathy with less therapy complexity.

Structural changes to quinolone analogs improve oral bioavailability, metabolic stability, and tumor killing while reducing toxicity.

Cycloserine-based ALS treatment inhibits TDP-43 aggregation, keeps the protein soluble, and helps reduce cell death linked to disease progression.

Blocking L1 reverse transcriptase with censavudine or elvucitabine downregulates IFN-I signaling to reduce age-associated inflammation.

Selective N-glycosylation weakens erythropoietic receptor binding while preserving neuroprotection and extending plasma half-life.

Combining UCBT with AAV-delivered GALC expression addresses peripheral nerve decline in Krabbe disease while improving myelination and survival.

RNAi agents silence ATXN3 mRNA through RISC cleavage, aiming to slow SCA3 progression while enabling sustained treatment effect.

Co-transplanted periventricular endothelial cells guide GABAergic interneurons, speeding brain integration and widening in vivo distribution.

microRNAs suppress STAT3, E2F6, and MAX pathways to restore adult glial progenitor cell proliferation, migration, and myelin production.

Targeted cereblon binders modify IMiD structure to boost T-cell activation across species while improving tumor and autoimmune therapy.

A polymer matrix stabilizes bupropion and dextromethorphan release, preventing ethanol dose dumping and high-fat meal food effects.

Taking an MCT emulsion 10-60 minutes before a meal raises blood ketones more than co-administration while avoiding GI side effects.

Formula I compounds improve selective Nav1.8 inhibition and pharmacokinetics, supporting treatment of pain and other channel-related diseases.

A high-purity oxytocin and V1a receptor antagonist suppresses uterine contractions quickly while enabling oral preterm labor treatment with fewer side effects.

A synergistic blend of palmitoylethanolamide, Salvia miltiorrhiza extract, and D-aspartate improves cognition with better tolerability.

Using the R-enantiomer of fenfluramine reduces seizure frequency in epilepsy and Dravet syndrome while lowering cardiotoxicity risk.

Highly purified CBD with minimal THC helps reduce Rett syndrome seizure frequency, including treatment-resistant tonic and absence seizures.

A kinetin-based approach directly modulates circadian phase, period, and amplitude to correct jet lag, shift-work disorder, and sleep disruption.

Heterobifunctional compounds recruit Tau to E3 ubiquitin ligases, enabling proteasomal degradation to reduce Tau buildup in tauopathies.

Co-formers turn psilocin into stable crystalline salts or co-crystals with better processing and tunable dissolution for psychiatric treatment.

Targets the S32A and S36A mutant sites in srIκB to distinguish it from wild-type IκB and support NF-κB pathway research and delivery.

A single-layer NAKET tablet uses a controlled-release matrix to maintain oral ketamine levels for 24-36 hours without toxic plasma spikes.

W68-targeting antibodies bind an epitope exposed only in misfolded TDP-43, enabling selective detection and blocking aggregate spread.

Conformational constraints improve 5-HT2C receptor selectivity while limiting 5-HT2A and 5-HT2B activation linked to CNS therapy side effects.

Blocking kappa opioid receptor signaling improves sleep fragmentation and daytime sleepiness in chronic pain without altering sensory pain thresholds.

Selective deuterium enrichment in ibogaine aims to relieve withdrawal and cravings rapidly while reducing side effects and addiction risk.

Anti-CGRP antibodies address migraine’s most bothersome symptoms beyond headache, improving MBS and PGIC within 1 month.

Extended-release phenylalkylamino carbamates treat ADHD while improving compliance and reducing side effects and abuse potential.

A modified GLP-1/Gcg peptide resists DPP-IV degradation to extend half-life, maintain activity, and reduce dosing frequency.

Specific cyano and cyclic hydrazine features improve JAK1/JAK2 selectivity, helping treat autoimmune disease with fewer side effects.

Combining GM-CSF and IL-2 boosts Treg numbers and activity to restore immune tolerance, reduce neuroinflammation, and slow disease progression.

Anionic polymers block Aβ-oligomer binding to cellular prion protein, offering a therapeutic route to restore synaptic plasticity and memory.

A nanoparticle composition with resveratrol or curcumin improves OSA symptom relief while avoiding costly, low-compliance mechanical treatments.

NRF2 activators target KEAP1-NRF2 signaling to reduce oxidative stress and support blood-brain barrier function in cerebral small vessel disease.

Controlled-release low-dose 5HT agonist formulations improve cognition and mood while keeping plasma levels below hallucinogenic thresholds.

Specific IL-15 mutations tune IL-15Rβ and γc binding, enabling soluble receptor-mediated activation without cell-to-cell contact.

Pooled umbilical cord blood exosomes offer a wider post-stroke treatment window, reducing infarct size, inflammation, and neural injury symptoms.

Cyclized IGFBP peptide fragments aim to deliver disease-modifying CNS and neurodevelopmental therapy with minimal side effects.

Defined growth factor conditions produce high-purity Schwann cells for authentic disease modeling, therapeutic screening, and regenerative use.

Using the miR-25802 cluster as a biomarker improves early AD diagnosis and enables targeted control of microglial inflammation.

Low-dose 5HT receptor agonist formulations improve motivation, attention, and cognitive engagement while limiting hallucinations and other side effects.

Crystalline Blarcamesine salt forms improve formulation, stability, dissolution, and bioavailability while supporting controlled pharmaceutical processing.

A modified TAT-FXN fusion polypeptide improves solubility at physiological pH, enabling higher-concentration dosing for Friedreich's ataxia.

Truncated TβRII-Fc fusion polypeptides selectively bind GDF15, TGFβ1, and TGFβ3 to block ligand-receptor signaling in disease.

D-peptides selected to bind native tau monomers stabilize folded tau and break toxic oligomers and fibrils into monomers.

Systemic FcRn inhibition blocks CNS-to-blood transcytosis of locally delivered therapeutic polypeptides, preserving tissue levels and reducing side effects.

Oxadiazole-core KCNT1 inhibitors selectively modulate sodium-activated potassium channels to treat epilepsy and related hyperexcitability disorders.

A D-amino acid C/EBPβ antagonist peptide disrupts ATF5-linked interactions to induce tumor cell death in solid tumors.

Targeted deubiquitinases restore trafficking-deficient ion channels by removing ubiquitin chains and boosting membrane protein expression.

Subcutaneous saline infusion maintains therapeutic uridine levels for rapid neuroprotection while avoiding IV hyperthermia, phlebitis, and central access.

A Wnt5a peptide derivative targets glioma cancer stem cells to reduce tumor growth and migration.

EV1018 and EV1019 human monoclonal antibodies bind hGM-CSF with high affinity to neutralize its activity.

IL-20 antagonists target specific cytokine pathways to alleviate chronic inflammatory pain without affecting other physiological functions.

Extracting placental microvesicles carrying syncytin-1 from maternal blood provides accurate preeclampsia diagnosis without invasive procedures.

Isolating S-BHB from ketogenic diets resolves the trade-off between therapeutic efficacy and patient adherence.

Transition metal tricarbonyl complexes with benzo-heterocyclic ligands cross the blood-brain barrier via passive diffusion driven by optimized lipophilicity.

Placental stem cells accelerate kidney recovery by secreting trophic factors, addressing the lack of specific therapies for acute kidney injury.

Engineered zinc finger proteins bind specific trinucleotide repeat sequences to modulate gene expression in therapeutic compositions.

Novel bicyclic compound inhibits PRMT5 enzyme activity, suppressing tumor cell proliferation where existing therapies fail.

A transdermal therapeutic system uses a multi-component enhancer to increase vinpocetine permeation rate.

Novel heterocyclic compounds activate NF-kB signaling to deliver neuroprotective effects and enhance memory performance in neuronal cells.

Cancer exosomes deliver inhibitory RNAs with RISC complexes to bypass saturation of endogenous biogenesis pathways.

Porous nanoparticles with controlled pore sizes load myelin-derived self-antigens to induce immune tolerance, suppressing autoimmune responses against myelin.

Lactobacillus plantarum PS128 reduces visceral hypersensitivity and stress symptoms by regulating serotonin metabolism without adverse side effects.

Alpha-amino boronic acid derivatives inhibit LMP7 to avoid constitutive proteasome side effects in autoimmune treatment.

Combining CSF-1R inhibitors with PI3K, IL4, NFAT, and Stat6 blockers prevents tumor recurrence caused by drug resistance.

Formula I naphthalene derivatives target cholinergic, glutamatergic, and mitochondrial systems via a single molecular entity.

Crosslinked acrylic acid polymer buffers skin moisture variability in rivastigmine transdermal compositions, ensuring consistent therapeutic flux.

Antibody-based immunoassays replace complex chromatography to enable point-of-care monitoring of antipsychotic drug levels.

Amphiphilic pyridinium compounds block AXL expression and suppress IL-8 to overcome limited efficacy in epilepsy and viral infections.

Heterocycle fused gamma carboline prodrugs deliver sustained therapeutic concentrations via metabolic conversion to active compounds.

Administering oxytocin or analogs alleviates Parkinson's symptoms while avoiding invasive procedures and adverse side effects of traditional therapies.

SARM1 inhibitors block axonal degeneration by preserving NAD+ levels, addressing the lack of effective treatments for neurodegenerative diseases.

Selective breeding of tobacco cultivar AOB 171 reduces nicotine content while preserving yield and smoking characteristics.

Culture supernatant of fetal appendage cells promotes cranial neural progenitor cell proliferation and survival.

Quantifying specific miRNA pairs in bodily fluids detects neurodegenerative disorders early, bypassing late-stage neuronal loss.

Alcohol extraction isolates Ginkgo biloba ketone ester with controlled compound concentrations, preventing adulteration and ensuring batch consistency.

Clostridial neurotoxin activates microglia to clear damaged neural tissue and accelerate endogenous repair mechanisms.

Novel amyloid beta peptides induce specific antibody responses without adjuvants.

Adipose stem cell conditioned media delivers angiogenic and antiapoptotic factors to promote neural tissue repair.

Soluble CD137 and CD137-expressing regulatory T cells suppress autoreactive T cell activation, reversing ineffective autoimmune therapies.

Igmesine reduces beta-amyloid burden and neuronal apoptosis by optimizing molecular parameters for enhanced blood-brain barrier penetration.

Nanoscale carotenoid dispersions improve gastrointestinal solubility and brain delivery, reducing oxidative stress in neurodegenerative disorders.

Concentrated tobacco alkaloid injection eliminates dependence without long-term regimens or side effects.

Sulfamate derivative compounds deliver enhanced anti-epileptic activity with reduced side effects, addressing treatment gaps in resistant epilepsy patients.

Mirtazapine treats medication overuse headache by reducing withdrawal symptoms and restoring acute analgesic responsiveness during tapering.

Hydroxyl purine compounds inhibit phosphodiesterase 2 activity through specific ring substitutions.

Crystalline oxytocin receptor antagonist enables oral tocolytic therapy, reducing uterine contractions without adverse maternal or fetal effects.

Combining benzoic acid derivatives with neuropharmaceuticals increases treatment efficacy for neuropsychiatric disorders.

Combining a nicotinic agonist with a non-psychoactive cannabinoid in a single delivery system addresses both physiological deficiency and emotional cravings.

Purified cannabidiol extract lowers total seizure counts by 69% in treatment-resistant Aicardi syndrome patients unresponsive to standard anti-epileptic drugs.

Hyaluronan culture conditions drive pluripotent stem cells into mortal progenitors, reducing teratoma risk while preserving lineage potential.

A bacterial strain mixture modulates sleep quality and mood stability through gut-brain communication pathways.

Selective CD19 targeting treats multiple sclerosis without depleting protective immune cells, avoiding long-term immunosuppression.

A carbamate compound prevents migraine attacks by inhibiting cortical spreading depression and stabilizing the nervous system.

Engineered reprogramming factors delivered via synthetic messenger RNA convert human fibroblasts into induced pluripotent stem cells without viral vectors.

Combining blood biomarker expression levels with mobile app questionnaires predicts suicidality in females, bypassing unreliable self-reporting stigma.

NAP peptides enhance tau-tubulin binding to inhibit neurofibrillary tangle formation and reduce tau hyper-phosphorylation.